Modulation of collagen-induced arthritis by adenovirus-mediated intra-articular expression of modified collagen type II

Arthritis Research and Therapy

Volumn 12, Issue 4, 2010, Pages

  Tang, Bo ^a   Cullins, David L ^a   Zhou, Jing ^a   Zawaski, Janice A ^a   Park, Hyelee ^a   Brand, David D ^a,b   Hasty, Karen A ^a   Gaber, M Waleed ^a   Stuart, John M ^a,b   Kang, Andrew H ^a,b   Myers, Linda K ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COLLAGEN; COLLAGEN TYPE 2; INTERLEUKIN 4; LUCIFERASE; PEPTIDE; RECOMBINANT COLLAGEN TYPE 2 CB11; RECOMBINANT COLLAGEN TYPE 2 CB11 A9; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BIOLUMINESCENCE; COLLAGEN INDUCED ARTHRITIS; CONTROLLED STUDY; CYTOKINE RELEASE; GENE TARGETING; GENE THERAPY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; POINT MUTATION; POLYMERASE CHAIN REACTION; REPORTER GENE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; ANIMAL; BACULOVIRUS; DBA MOUSE; DRUG EFFECT; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTRAARTICULAR DRUG ADMINISTRATION; JOINT; METHODOLOGY; SYNOVIUM;

ADENOVIRIDAE; ANIMALS; ARTHRITIS, EXPERIMENTAL; BACULOVIRIDAE; COLLAGEN TYPE II; GENE THERAPY; IMMUNOSUPPRESSION; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN-4; JOINTS; MICE; MICE, INBRED DBA; RECOMBINANT PROTEINS; SYNOVIAL MEMBRANE; T-LYMPHOCYTES;

EID: 78651465342     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3074     Document Type: Article

References (28)

1. Kukar M, Petryna O, Efthimiou P. Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. Biologics 2009, 3:443-457. 2763315, 19851470.
2. Lakatos PL, Miheller P. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?. Curr Drug Targets 2010, 11:179-86. 10.2174/138945010790309867, 20210767.
3. Evans CH, Ghivizzani SC, Robbins PD. Gene therapy of the rheumatic diseases: 1998 to 2008. Arthritis Res Ther 2009, 11:209. 10.1186/ar2563, 2688220, 19232068.
4. Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE, Wiesenhutter CW, Willis L, Ruderman EM, Forstot JZ, Maricic MJ, Dao KH, Pritchard CH, Fiske DN, Burch FX, Prupas HM, Anklesaria P, Heald AE. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J Rheumatol 2010, 37:692-703. 10.3899/jrheum.090817, 20032102.
5. Rabinovich GA, Daly G, Dreja H, Tailor H, Riera CM, Hirabayashi J, Chernajovsky Y. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 1999, 190:385-398. 10.1084/jem.190.3.385, 2195592, 10430627.
6. Chan JM, Villarreal G, Jin WW, Stepan T, Burstein H, Wahl SM. Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther 2002, 6:727-736. 10.1006/mthe.2002.0808, 12498769.
7. Khoury M, Courties G, Fabre S, Bouffi C, Seemayer CA, Vervoordeldonk MJ, Tak PP, Jorgensen C, Apparailly F. Adeno-associated virus type 5-mediated intraarticular administration of tumor necrosis factor small interfering RNA improves collagen-induced arthritis. Arthritis Rheum 2010, 62:765-770. 10.1002/art.27302, 20187132.
8. Myers LK, Tang B, Rosioniec EF, Stuart JM, Kang AH. An altered peptide ligand of type II collagen suppresses autoimmune arthritis. Crit Rev Immunol 2007, 27:345-356.
9. Stuart JM, Cremer MA, Dixit SN, Kang AH, Townes AS. Collagen-induced arthritis in rats. Comparison of vitreous and cartilage-derived collagens. Arthritis Rheum 1979, 22:347-352. 10.1002/art.1780220406, 426881.
10. Rosloniec EF, Kang AH, Myers LK, Cremer MA. Collagen-induced arthritis. Current Protocols in Immunology 2010, 15.5.1-15.5.25. New York, NY: Wiley & Sons, Coico R, Shevach E.
11. Kingston RE, Chen CA, Rose JK. Calcium phosphate transfection. Curr Protoc Mol Biol 2003, Chapter 9:Unit 9.1.
12. Lu Y, Zhang Y, Steiner MS. Efficient identification of recombinant adenoviruses by direct plaque screening. DNA Cell Biol 1998, 17:643-645. 10.1089/dna.1998.17.643, 9703023.
13. Nokelainen M, Helaakoski T, Myllyharju J, Notbohm H, Pihlajaniemi T, Fietzek PP, Kivirikko KI. Expression and characterization of recombinant human type II collagens with low and high contents of hydroxylysine and its glycosylated forms. Matrix Biol 1998, 16:329-338. 10.1016/S0945-053X(98)90004-X, 9503366.
14. Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, Kang AH. Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol 1998, 161:3589-3595.
15. Latham KA, Whittington KB, Zhou R, Qian Z, Rosloniec EF. Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints. J Immunol 2005, 174:3978-3985.
16. Myers LK, Tang B, Stuart JM, Kang AH. The role of IL-4 in regulation of murine collagen-induced arthritis. Clin Immunol 2002, 102:185-191. 10.1006/clim.2001.5162, 11846461.
17. Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH. Development and validation of gene therapies in autoimmune diseases: Epidemiology to animal models. Autoimmun Rev 2010, 9:A400-405. 10.1016/j.autrev.2009.12.009, 20035901.
18. Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, Barranger JA, Elders EM, Gay S, Tomaino MM, Wasko MC, Watkins SC, Whiteside TL, Glorioso JC, Lotze MT, Wright TM. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996, 7:1261-1280. 10.1089/hum.1996.7.10-1261, 8793551.
19. Wehling P, Reinecke J, Baltzer AA, Granrath M, Schulitz KP, Schultz C, Krauspe R, Whiteside T, Elder E, Ghivizzani SC, Robbins PD, Evans CH. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum Gene Ther 2009, 20:97-101. 10.1089/hum.2008.075, 2855248, 18986219.
20. Takayanagi H, Juji T, Miyazaki T, Iizuka H, Takahashi T, Isshiki M, Okada M, Tanaka Y, Koshihara Y, Oda H, Kurokawa T, Nakamura K, Tanaka S. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest 1999, 104:137-146. 10.1172/JCI6093, 408475, 10411542.
21. Zhang H, Yang Y, Horton JL, Samoilova EB, Judge TA, Turka LA, Wilson JM, Chen Y. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997, 100:1951-1957. 10.1172/JCI119726, 508384, 9329958.
22. Ghivizzani SC, Lechman ER, Tio C, Mule KM, Chada S, McCormack JE, Evans CH, Robbins PD. Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy. Gene Ther 1997, 4:977-982. 10.1038/sj.gt.3300486, 9349435.
23. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010, 17:295-304. 10.1038/gt.2009.148, 19907498.
24. Backlund J, Carlsen S, Hoger T, Holm B, Fugger L, Kihlberg J, Burkhardt H, Holmdahl R. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA 2002, 99:9960-9965. 10.1073/pnas.132254199, 126607, 12089323.
25. Corthay A, Backlund J, Holmdahl R. Role of glycopeptide-specific T cells in collagen-induced arthritis: an example how post-translational modification of proteins may be involved in autoimmune disease. Ann Med 2001, 33:456-465. 10.3109/07853890109002094, 11680793.
26. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R. T cell recognition of carbohydrates on type II collagen. J Exp Med 1994, 180:745-749. 10.1084/jem.180.2.745, 2191590, 8046350.
27. Dzhambazov B, Nandakumar KS, Kihlberg J, Fugger L, Holmdahl R, Vestberg M. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J Immunol 2006, 176:1525-1533.
28. Myers LK, Sakurai Y, Rosloniec EF, Stuart JM, Kang AH. An analog peptide that suppresses collagen-induced arthritis. Am J Med Sci 2004, 327:212-216. 10.1097/00000441-200404000-00007, 15084917.